{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:12:45Z","timestamp":1793229165183,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T00:00:00Z","timestamp":1516752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T00:00:00Z","timestamp":1516752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antibiotic resistance poses rapidly increasing global problems in combatting multidrug-resistant (MDR) infectious diseases like MDR tuberculosis, prompting for novel approaches including host-directed therapies (HDT). Intracellular pathogens like<jats:italic>Salmonellae<\/jats:italic>and<jats:italic>Mycobacterium tuberculosis<\/jats:italic>(<jats:italic>Mtb<\/jats:italic>) exploit host pathways to survive. Only very few HDT compounds targeting host pathways are currently known. In a library of pharmacologically active compounds (LOPAC)-based drug-repurposing screen, we identify multiple compounds, which target receptor tyrosine kinases (RTKs) and inhibit intracellular<jats:italic>Mtb<\/jats:italic>and Salmonellae more potently than currently known HDT compounds. By developing a data-driven in silico model based on confirmed targets from public databases, we successfully predict additional efficacious HDT compounds. These compounds target host RTK signaling and inhibit intracellular (MDR)<jats:italic>Mtb<\/jats:italic>. A complementary human kinome siRNA screen independently confirms the role of RTK signaling and kinases (BLK, ABL1, and NTRK1) in host control of<jats:italic>Mtb<\/jats:italic>. These approaches validate RTK signaling as a drugable host pathway for HDT against intracellular bacteria.<\/jats:p>","DOI":"10.1038\/s41467-017-02777-6","type":"journal-article","created":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T15:22:40Z","timestamp":1516288960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6570-6069","authenticated-orcid":false,"given":"Cornelis J.","family":"Korbee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias T.","family":"Heemskerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragi","family":"Kocev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"van Strijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Rabiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kees L. M. C.","family":"Franken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel D. L.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u0161o","family":"D\u017eeroski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00eblle C.","family":"Haks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom H. M.","family":"Ottenhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,24]]},"reference":[{"key":"2777_CR1","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1128\/IAI.01126-10","volume":"79","author":"CR Diedrich","year":"2011","unstructured":"Diedrich, C. R. & Flynn, J. L. HIV-1\/mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis? Infect. Immun. 79, 1407\u20131417 (2011).","journal-title":"Infect. Immun."},{"key":"2777_CR2","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.5588\/ijtld.12.0479","volume":"16","author":"THM Ottenhoff","year":"2012","unstructured":"Ottenhoff, T. H. M. The knowns and unknowns of the immunopathogenesis of tuberculosis. Int. J. Tuberc. Lung Dis. 16, 1424\u20131432 (2012).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"2777_CR3","unstructured":"World Health Organization. Global Tuberculosis Report 2015 (WHO, Geneva, 2015)."},{"key":"2777_CR4","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1002\/eji.200939518","volume":"39","author":"THM Ottenhoff","year":"2009","unstructured":"Ottenhoff, T. H. M. Overcoming the global crisis: \u2018yes, we can\u2019, but also for TB\u2026? Eur. J. Immunol. 39, 2014\u20132020 (2009).","journal-title":"Eur. J. Immunol."},{"issue":"Suppl 3","key":"2777_CR5","doi-asserted-by":"publisher","first-page":"S156","DOI":"10.1086\/651486","volume":"50","author":"MS Jassal","year":"2010","unstructured":"Jassal, M. S. & Bishai, W. R. Epidemiology and challenges to the elimination of global tuberculosis. Clin. Infect. Dis. 50(Suppl 3), S156\u2013S164 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"2777_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.tim.2012.06.002","volume":"20","author":"THM Ottenhoff","year":"2012","unstructured":"Ottenhoff, T. H. M. New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol. 20, 419\u2013428 (2012).","journal-title":"Trends Microbiol."},{"key":"2777_CR7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.cbpa.2010.04.008","volume":"14","author":"CE Barry","year":"2010","unstructured":"Barry, C. E. & Blanchard, J. S. The chemical biology of new drugs in the development for tuberculosis. Curr. Opin. Chem. Biol. 14, 456\u2013466 (2010).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"2777_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1473-3099(05)70086-4","volume":"5","author":"SR Norrby","year":"2005","unstructured":"Norrby, S. R., Nord, C. E. & Finch, R. European Society of Clinical Microbiology and Infectious Diseases. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis. 5, 115\u2013119 (2005).","journal-title":"Lancet Infect. Dis."},{"key":"2777_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nature04616","volume":"440","author":"D Becker","year":"2006","unstructured":"Becker, D. et al. Robust Salmonella metabolism limits possibilities for new antimicrobials. Nature 440, 303\u2013307 (2006).","journal-title":"Nature"},{"key":"2777_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1126\/science.1171583","volume":"324","author":"V Makarov","year":"2009","unstructured":"Makarov, V. et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324, 801\u2013804 (2009).","journal-title":"Science"},{"key":"2777_CR11","doi-asserted-by":"publisher","first-page":"e1000645","DOI":"10.1371\/journal.ppat.1000645","volume":"5","author":"T Christophe","year":"2009","unstructured":"Christophe, T. et al. High content screening identifies decaprenyl-phosphoribose 2\u2019 epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 5, e1000645 (2009).","journal-title":"PLoS Pathog."},{"key":"2777_CR12","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nm.1950","volume":"15","author":"N Willand","year":"2009","unstructured":"Willand, N. et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat. Med. 15, 537\u2013544 (2009).","journal-title":"Nat. Med."},{"key":"2777_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0140-6736(10)62173-3","volume":"378","author":"SD Lawn","year":"2011","unstructured":"Lawn, S. D. & Zumla, A. I. Tuberculosis. Lancet 378, 57\u201372 (2011).","journal-title":"Lancet"},{"key":"2777_CR14","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nchembio.1917","volume":"11","author":"R Guler","year":"2015","unstructured":"Guler, R. & Brombacher, F. Host-directed drug therapy for tuberculosis. Nat. Chem. Biol. 11, 748\u2013751 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"2777_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/imr.12255","volume":"264","author":"TR Hawn","year":"2015","unstructured":"Hawn, T. R., Shah, J. A. & Kalman, D. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics. Immunol. Rev. 264, 344\u2013362 (2015).","journal-title":"Immunol. Rev."},{"key":"2777_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nature06345","volume":"450","author":"C Kuijl","year":"2007","unstructured":"Kuijl, C. et al. Intracellular bacterial growth is controlled by a kinase network around PKB\/AKT1. Nature 450, 725\u2013730 (2007).","journal-title":"Nature"},{"key":"2777_CR17","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.cell.2010.02.012","volume":"140","author":"D Kumar","year":"2010","unstructured":"Kumar, D. et al. Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. Cell 140, 731\u2013743 (2010).","journal-title":"Cell"},{"key":"2777_CR18","doi-asserted-by":"publisher","first-page":"e1000839","DOI":"10.1371\/journal.ppat.1000839","volume":"6","author":"S Jayaswal","year":"2010","unstructured":"Jayaswal, S. et al. Identification of host-dependent survival factors for intracellular Mycobacterium tuberculosis through an siRNA screen. PLoS Pathog. 6, e1000839 (2010).","journal-title":"PLoS Pathog."},{"key":"2777_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.chom.2013.01.008","volume":"13","author":"V Sundaramurthy","year":"2013","unstructured":"Sundaramurthy, V. et al. Integration of chemical and RNAi multiparametric profiles identifies triggers of intracellular mycobacterial killing. Cell Host Microbe 13, 129\u2013142 (2013).","journal-title":"Cell Host Microbe"},{"key":"2777_CR20","doi-asserted-by":"publisher","first-page":"e0149326","DOI":"10.1371\/journal.pone.0149326","volume":"11","author":"D Machado","year":"2016","unstructured":"Machado, D. et al. Ion channel blockers as antimicrobial agents, efflux inhibitors, and enhancers of macrophage killing activity against drug resistant Mycobacterium tuberculosis. PLoS ONE 11, e0149326 (2016).","journal-title":"PLoS ONE"},{"key":"2777_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.chom.2011.09.010","volume":"10","author":"RJ Napier","year":"2011","unstructured":"Napier, R. J. et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 10, 475\u2013485 (2011).","journal-title":"Cell Host Microbe"},{"key":"2777_CR22","doi-asserted-by":"publisher","first-page":"e1002262","DOI":"10.1371\/journal.ppat.1002262","volume":"7","author":"S Subbian","year":"2011","unstructured":"Subbian, S. et al. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog. 7, e1002262 (2011).","journal-title":"PLoS Pathog."},{"key":"2777_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ajpath.2011.03.039","volume":"179","author":"S Subbian","year":"2011","unstructured":"Subbian, S. et al. Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am. J. Pathol. 179, 289\u2013301 (2011).","journal-title":"Am. J. Pathol."},{"key":"2777_CR24","doi-asserted-by":"publisher","first-page":"e17091","DOI":"10.1371\/journal.pone.0017091","volume":"6","author":"MS Koo","year":"2011","unstructured":"Koo, M.-S. et al. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS ONE 6, e17091 (2011).","journal-title":"PLoS ONE"},{"key":"2777_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/infdis\/jit152","volume":"208","author":"C Vilaplana","year":"2013","unstructured":"Vilaplana, C. et al. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J. Infect. Dis. 208, 199\u2013202 (2013).","journal-title":"J. Infect. Dis."},{"key":"2777_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature13489","volume":"511","author":"KD Mayer-Barber","year":"2014","unstructured":"Mayer-Barber, K. D. et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511, 99\u2013103 (2014).","journal-title":"Nature"},{"key":"2777_CR27","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1073\/pnas.1424563112","volume":"112","author":"M Datta","year":"2015","unstructured":"Datta, M. et al. Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc. Natl Acad. Sci. USA 112, 1827\u20131832 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2777_CR28","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nature13967","volume":"517","author":"SH Oehlers","year":"2015","unstructured":"Oehlers, S. H. et al. Interception of host angiogenic signalling limits mycobacterial growth. Nature 517, 612\u2013615 (2015).","journal-title":"Nature"},{"key":"2777_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.15252\/emmm.201404137","volume":"7","author":"M Schiebler","year":"2015","unstructured":"Schiebler, M. et al. Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion. EMBO Mol. Med. 7, 127\u2013139 (2015).","journal-title":"EMBO Mol. Med."},{"key":"2777_CR30","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/jac\/dku166","volume":"69","author":"C Skerry","year":"2014","unstructured":"Skerry, C. et al. Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. J. Antimicrob. Chemother. 69, 2453\u20132457 (2014).","journal-title":"J. Antimicrob. Chemother."},{"key":"2777_CR31","doi-asserted-by":"publisher","first-page":"e1003946","DOI":"10.1371\/journal.ppat.1003946","volume":"10","author":"SA Stanley","year":"2014","unstructured":"Stanley, S. A. et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog. 10, e1003946 (2014).","journal-title":"PLoS Pathog."},{"key":"2777_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1146\/annurev.cellbio.20.010403.114015","volume":"20","author":"I Vergne","year":"2004","unstructured":"Vergne, I., Chua, J., Singh, S. B. & Deretic, V. Cell biology of mycobacterium tuberculosis phagosome. Annu. Rev. Cell Dev. Biol. 20, 367\u2013394 (2004).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"2777_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.mib.2003.12.005","volume":"7","author":"JH Brumell","year":"2004","unstructured":"Brumell, J. H. & Grinstein, S. Salmonella redirects phagosomal maturation. Curr. Opin. Microbiol. 7, 78\u201384 (2004).","journal-title":"Curr. Opin. Microbiol."},{"key":"2777_CR34","doi-asserted-by":"publisher","first-page":"263ra159","DOI":"10.1126\/scitranslmed.3009885","volume":"6","author":"A Singhal","year":"2014","unstructured":"Singhal, A. et al. Metformin as adjunct antituberculosis therapy. Sci. Transl. Med. 6, 263ra159 (2014).","journal-title":"Sci. Transl. Med."},{"key":"2777_CR35","doi-asserted-by":"publisher","first-page":"e1005007","DOI":"10.1371\/journal.ppat.1005007","volume":"11","author":"AK Coussens","year":"2015","unstructured":"Coussens, A. K., Wilkinson, R. J. & Martineau, A. R. Phenylbutyrate is bacteriostatic against Mycobacterium tuberculosis and regulates the macrophage response to infection, synergistically with 25-hydroxy-vitamin D3. PLoS Pathog. 11, e1005007 (2015).","journal-title":"PLoS Pathog."},{"key":"2777_CR36","doi-asserted-by":"publisher","first-page":"e0138340","DOI":"10.1371\/journal.pone.0138340","volume":"10","author":"A Mily","year":"2015","unstructured":"Mily, A. et al. Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: a randomized controlled trial. PLoS ONE 10, e0138340 (2015).","journal-title":"PLoS ONE"},{"key":"2777_CR37","doi-asserted-by":"publisher","first-page":"e1004265","DOI":"10.1371\/journal.ppat.1004265","volume":"10","author":"P Mehrotra","year":"2014","unstructured":"Mehrotra, P. et al. Pathogenicity of Mycobacterium tuberculosis is expressed by regulating metabolic thresholds of the host macrophage. PLoS Pathog. 10, e1004265 (2014).","journal-title":"PLoS Pathog."},{"key":"2777_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd.2017.162","volume":"17","author":"SHE Kaufmann","year":"2017","unstructured":"Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S. & Bartenschlager, R. Host-directed therapies for bacterial and viral infections. Nat. Rev. Drug Discov. 17, 35\u201356 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2777_CR39","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0898-6568(98)00012-6","volume":"10","author":"WS Liu","year":"1998","unstructured":"Liu, W. S. & Heckman, C. A. The sevenfold way of PKC regulation. Cell Signal. 10, 529\u2013542 (1998).","journal-title":"Cell Signal."},{"key":"2777_CR40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1042\/BJ20130220","volume":"452","author":"AX Wu-zhang","year":"2013","unstructured":"Wu-zhang, A. X. & Newton, A. C. Protein kinase C pharmacology: refining the toolbox. Biochem. J. 452, 195\u2013209 (2013).","journal-title":"Biochem. J."},{"key":"2777_CR41","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1006\/excr.1993.1102","volume":"205","author":"IC Le Poole","year":"1993","unstructured":"Le Poole, I. C. et al. Phagocytosis by normal human melanocytes in vitro. Exp. Cell Res. 205, 388\u2013395 (1993).","journal-title":"Exp. Cell Res."},{"key":"2777_CR42","doi-asserted-by":"crossref","first-page":"7284","DOI":"10.4049\/jimmunol.151.12.7284","volume":"151","author":"IC Le Poole","year":"1993","unstructured":"Le Poole, I. C. et al. A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J. Immunol. 151, 7284\u20137292 (1993).","journal-title":"J. Immunol."},{"key":"2777_CR43","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S0960-9822(06)00414-3","volume":"7","author":"SM van Ham","year":"1997","unstructured":"van Ham, S. M. et al. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading. Curr. Biol. 7, 950\u2013957 (1997).","journal-title":"Curr. Biol."},{"key":"2777_CR44","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1084\/jem.191.7.1127","volume":"191","author":"M van Ham","year":"2000","unstructured":"van Ham, M. et al. Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO. J. Exp. Med. 191, 1127\u20131136 (2000).","journal-title":"J. Exp. Med."},{"key":"2777_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/35095558","volume":"1","author":"SH Kaufmann","year":"2001","unstructured":"Kaufmann, S. H. How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol. 1, 20\u201330 (2001).","journal-title":"Nat. Rev. Immunol."},{"key":"2777_CR46","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S1286-4579(01)01495-2","volume":"3","author":"RL Santos","year":"2001","unstructured":"Santos, R. L. et al. Animal models of Salmonella infections: enteritis versus typhoid fever. Microbes Infect. 3, 1335\u20131344 (2001).","journal-title":"Microbes Infect."},{"key":"2777_CR47","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1021\/jm800984v","volume":"52","author":"S Howard","year":"2009","unstructured":"Howard, S. et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J. Med. Chem. 52, 379\u2013388 (2009).","journal-title":"J. Med. Chem."},{"key":"2777_CR48","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-10-0325","volume":"16","author":"JJ Tentler","year":"2010","unstructured":"Tentler, J. J. et al. Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin. Cancer Res. 16, 2989\u20132998 (2010).","journal-title":"Clin. Cancer Res."},{"key":"2777_CR49","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1182\/blood-2004-10-3913","volume":"105","author":"S Trudel","year":"2005","unstructured":"Trudel, S. et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105, 2941\u20132948 (2005).","journal-title":"Blood"},{"key":"2777_CR50","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2017","unstructured":"Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 45, D353\u2013D361 (2017).","journal-title":"Nucleic Acids Res."},{"key":"2777_CR51","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","volume":"141","author":"MA Lemmon","year":"2010","unstructured":"Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117\u20131134 (2010).","journal-title":"Cell"},{"key":"2777_CR52","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1126\/science.7892601","volume":"267","author":"A Levitzki","year":"1995","unstructured":"Levitzki, A. & Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science 267, 1782\u20131788 (1995).","journal-title":"Science"},{"key":"2777_CR53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0014-2999(02)02220-3","volume":"451","author":"EV Varga","year":"2002","unstructured":"Varga, E. V. et al. Involvement of Raf-1 in chronic delta-opioid receptor agonist-mediated adenylyl cyclase superactivation. Eur. J. Pharmacol. 451, 101\u2013102 (2002).","journal-title":"Eur. J. Pharmacol."},{"key":"2777_CR54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.biocel.2013.11.014","volume":"46","author":"I Cicha","year":"2014","unstructured":"Cicha, I., Zitzmann, R. & Goppelt-Struebe, M. Dual inhibition of Src family kinases and Aurora kinases by SU6656 modulates CTGF (connective tissue growth factor) expression in an ERK-dependent manner. Int. J. Biochem. Cell Biol. 46, 39\u201348 (2014).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2777_CR55","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1074-5521(00)00025-9","volume":"7","author":"MP Coghlan","year":"2000","unstructured":"Coghlan, M. P. et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7, 793\u2013803 (2000).","journal-title":"Chem. Biol."},{"key":"2777_CR56","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/jac\/dkv018","volume":"70","author":"MAA Al-Bari","year":"2015","unstructured":"Al-Bari, M. A. A. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J. Antimicrob. Chemother. 70, 1608\u20131621 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"2777_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-9-13","volume":"9","author":"R Ehsanian","year":"2011","unstructured":"Ehsanian, R., Van Waes, C. & Feller, S. M. Beyond DNA binding - a review of the potential mechanisms mediating quinacrine\u2019s therapeutic activities in parasitic infections, inflammation, and cancers. Cell Commun. Signal. 9, 13 (2011).","journal-title":"Cell Commun. Signal."},{"key":"2777_CR58","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/JCP.0b013e3182983ffa","volume":"33","author":"IM Lako","year":"2013","unstructured":"Lako, I. M., van den Heuvel, E. R., Knegtering, H., Bruggeman, R. & Taxis, K. Estimating dopamine D2 receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J. Clin. Psychopharmacol. 33, 675\u2013681 (2013).","journal-title":"J. Clin. Psychopharmacol."},{"key":"2777_CR59","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1152\/physrev.1999.79.3.763","volume":"79","author":"MP Blaustein","year":"1999","unstructured":"Blaustein, M. P. & Lederer, W. J. Sodium\/calcium exchange: its physiological implications. Physiol. Rev. 79, 763\u2013854 (1999).","journal-title":"Physiol. Rev."},{"key":"2777_CR60","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2007.04.043","volume":"130","author":"R Jayachandran","year":"2007","unstructured":"Jayachandran, R. et al. Survival of mycobacteria in macrophages is mediated by coronin 1-dependent activation of calcineurin. Cell 130, 37\u201350 (2007).","journal-title":"Cell"},{"key":"2777_CR61","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1097\/00005344-198913050-00011","volume":"13","author":"W Osterrieder","year":"1989","unstructured":"Osterrieder, W. & Holck, M. In vitro pharmacologic profile of Ro 40-5967, a novel Ca2+ channel blocker with potent vasodilator but weak inotropic action. J. Cardiovasc. Pharmacol. 13, 754\u2013759 (1989).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2777_CR62","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/ijc.29499","volume":"138","author":"AKA Gaumann","year":"2016","unstructured":"Gaumann, A. K. A. et al. Receptor tyrosine kinase inhibitors: Are they real tumor killers? Int. J. Cancer 138, 540\u2013554 (2016).","journal-title":"Int. J. Cancer"},{"key":"2777_CR63","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.3109\/10428194.2015.1091927","volume":"57","author":"AE Hay","year":"2016","unstructured":"Hay, A. E. et al. A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Leuk. Lymphoma 57, 1463\u20131466 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"2777_CR64","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1158\/1078-0432.CCR-14-1592","volume":"21","author":"L Moreno","year":"2015","unstructured":"Moreno, L. et al. A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin. Cancer Res. 21, 267\u2013273 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2777_CR65","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00432-016-2161-0","volume":"142","author":"N Sch\u00e4fer","year":"2016","unstructured":"Sch\u00e4fer, N. et al. Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. J. Cancer Res. Clin. Oncol. 142, 1581\u20131589 (2016).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2777_CR66","doi-asserted-by":"publisher","unstructured":"Cheng, A.-L. et al. Randomized, open-label phase 2 study comparing frontline dovitinib vs sorafenib in patients with advanced hepatocellular carcinoma. Hepatology https:\/\/doi.org\/10.1002\/hep.28600 (2016).","DOI":"10.1002\/hep.28600"},{"key":"2777_CR67","doi-asserted-by":"publisher","unstructured":"Lim, S. H. et al. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: a single-arm, phase 2 study. Cancer https:\/\/doi.org\/10.1002\/cncr.30135 (2016).","DOI":"10.1002\/cncr.30135"},{"key":"2777_CR68","doi-asserted-by":"publisher","unstructured":"Yee, K. W. L. et al. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia. Invest. New Drugs https:\/\/doi.org\/10.1007\/s10637-016-0375-2 (2016).","DOI":"10.1007\/s10637-016-0375-2"},{"key":"2777_CR69","doi-asserted-by":"publisher","first-page":"8001","DOI":"10.1038\/sj.onc.1208075","volume":"23","author":"SB Gauld","year":"2004","unstructured":"Gauld, S. B. & Cambier, J. C. Src-family kinases in B-cell development and signaling. Oncogene 23, 8001\u20138006 (2004).","journal-title":"Oncogene"},{"key":"2777_CR70","doi-asserted-by":"publisher","first-page":"14460","DOI":"10.1073\/pnas.0906474106","volume":"106","author":"M Borowiec","year":"2009","unstructured":"Borowiec, M. et al. Mutations at the BLK locus linked to maturity onset diabetes of the young and beta-cell dysfunction. Proc. Natl Acad. Sci. USA 106, 14460\u201314465 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2777_CR71","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2174\/187152708783885174","volume":"7","author":"SD Skaper","year":"2008","unstructured":"Skaper, S. D. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol. Disord. Drug Targets 7, 46\u201362 (2008).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"2777_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-239","volume":"10","author":"L Aloe","year":"2012","unstructured":"Aloe, L., Rocco, M. L., Bianchi, P. & Manni, L. Nerve growth factor: from the early discoveries to the potential clinical use. J. Transl. Med. 10, 239 (2012).","journal-title":"J. Transl. Med."},{"key":"2777_CR73","doi-asserted-by":"publisher","first-page":"5423","DOI":"10.1073\/pnas.90.12.5423","volume":"90","author":"PB Ehrhard","year":"1993","unstructured":"Ehrhard, P. B., Ganter, U., Stalder, A., Bauer, J. & Otten, U. Expression of functional trk protooncogene in human monocytes. Proc. Natl Acad. Sci. USA 90, 5423\u20135427 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2777_CR74","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pharmthera.2009.07.001","volume":"124","author":"T Maurice","year":"2009","unstructured":"Maurice, T. & Su, T.-P. The pharmacology of sigma-1 receptors. Pharmacol. Ther. 124, 195\u2013206 (2009).","journal-title":"Pharmacol. Ther."},{"key":"2777_CR75","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1189\/jlb.0105015","volume":"79","author":"FAW Verreck","year":"2006","unstructured":"Verreck, F. A. W., de Boer, T., Langenberg, D. M. L., van der Zanden, L. & Ottenhoff, T. H. M. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. J. Leukoc. Biol. 79, 285\u2013293 (2006).","journal-title":"J. Leukoc. Biol."},{"key":"2777_CR76","doi-asserted-by":"crossref","first-page":"648","DOI":"10.2144\/97234bm22","volume":"23","author":"BD Jett","year":"1997","unstructured":"Jett, B. D., Hatter, K. L., Huycke, M. M. & Gilmore, M. S. Simplified agar plate method for quantifying viable bacteria. Biotechniques 23, 648\u2013650 (1997).","journal-title":"Biotechniques"},{"key":"2777_CR77","doi-asserted-by":"publisher","first-page":"D447","DOI":"10.1093\/nar\/gku1003","volume":"43","author":"D Szklarczyk","year":"2015","unstructured":"Szklarczyk, D. et al. STRINGv10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447\u2013D452 (2015).","journal-title":"Nucleic Acids Res."},{"key":"2777_CR78","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1073\/pnas.0400983101","volume":"101","author":"FAW Verreck","year":"2004","unstructured":"Verreck, F. A. W. et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc. Natl Acad. Sci. USA 101, 4560\u20134565 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-02777-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-02777-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-02777-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T16:04:39Z","timestamp":1693497879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-02777-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,24]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["2777"],"URL":"https:\/\/doi.org\/10.1038\/s41467-017-02777-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,24]]},"assertion":[{"value":"25 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"358"}}